The ReVAMPP network will focus its research efforts on "prototype pathogens" and high-priority pathogens.

Friday, September 13, 2024 NIH Awards Establish Pandemic Preparedness Research Network The ReVAMPP network will support monoclonal antibody and vaccine research on pathogens from many different groups of viruses, including those shown here: hantavirus, yellow fever virus, Nipah virus, picornavirus, and Chikungunya. Microscopy captured at the NIAID Integrated Research Facility in Ft Detrick, MD.  Credit: NIAID NIH's National Institute of Allergy and Infectious Diseases (NIAID) has established a new pandemic preparedness research network, with the goal of developing effective vaccines and monoclonal antibodies. The Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Network will conduct research on "prototype pathogens," representative pathogens from virus families known to infect humans, and high-priority pathogens that have the potential to cause deadly diseases. Learn More National Institute of Allergy and Infectious Diseases  |  National Institutes of Health

---

Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. Your subscription may be removed if you do not open our emails for a six-month period. 

This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).

                           

---

This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107